Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729157 | 0.85 | NPC1 (0.46) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL9969945 | 0.83 | TAAR1 (0.48) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL1257788 | 0.83 | SRC (0.62) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL1257786 | 0.83 | NPSR1 (0.45) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL3031232 | 0.83 | TP53 (0.44) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL2702114 | 0.82 | ICMT (0.45) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL2530247 | 0.82 | P2RX7 (0.44) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL4681634 | 0.82 | NPC1 (0.44) | NPC1RAB9ASRCMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2530248 | 0.82 | SRC (0.61) | NPC1RAB9ASRCMEN1KMT2A | |
| SCHEMBL9268651 | 0.82 | NPC1 (0.44) | NPC1RAB9ASRCMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | APALENE TECHNOLOGY CO., LTD. (HANGZHOU) (CN) | 2019-10-15 | — | — | US | disclosed |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC | 2018-08-02 | — | — | US | disclosed |
| US-20180147571-A1 | NOVEL LINEAR ALPHA-OLEFIN CATALYSTS AND PREPARATION AND USE THEREOF | APALENE TECHNOLOGY CO., LTD. (JIAXING) (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009109999-A1 | NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS | LUPIN LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| US-4588749-A | ANTIOBESITY AND HYPOGLYCEMIC AGENTS | BEECHAM GROUP P.L.C. (GB) | 1986-05-13 | — | — | US | disclosed |
| EP-0040000-B1 | ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147571-A1 | NOVEL LINEAR ALPHA-OLEFIN CATALYSTS AND PREPARATION AND USE THEREOF | UBE2L3, RNF168, AGL | NPC1 3521/4885RAB9A 3123/4885SRC 3878/4885 |
| US-20180214413-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | NPC1 1496/4885RAB9A 3645/4885SRC 1195/4885 |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | NPC1 2858/4885RAB9A 1703/4885SRC 18/4885 |
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | UBE2L3, COG8, ACSL3 | NPC1 3364/4885RAB9A 3127/4885SRC 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.